Preferred Label : dabrafenib;

MeSH note : an antineoplastic agent that inhibits BRAF kinase; InChIKey: BFSMGDJOXZAERB-UHFFFAOYSA-N;

CISMeF synonym : GSK 2118436;

MeSH hyponym : GSK2118436; GSK-2118436;

Is substance : O;

UNII : QGP4HA4G1B;

InChIKey : BFSMGDJOXZAERB-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/dabrafenib
2024
false
false
false
France
French
dabrafenib
drug information
guidelines for drug use
administration, oral
summary of product characteristics
package leaflet
Disintegrating Tablet Dosage Form
glioma
dabrafenib
child
BRAF Inhibitor

---
https://www.ema.europa.eu/en/medicines/human/EPAR/finlee
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dabrafenib
dabrafenib
dabrafenib
drug approval
orphan drug production
glioma
malignant glioma
infant
child
antineoplastic combined chemotherapy protocols
Dabrafenib/Trametinib Regimen
Childhood Low Grade Glioma
Childhood Malignant Glioma
europe
Dabrafenib Mesylate
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
BRAF V600E Mutation Present
administration, oral
BRAF Inhibitor
proto-oncogene proteins b-raf
drug interactions
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib

---
https://www.has-sante.fr/jcms/p_3450970/en/dabrafenib-trametinib-novartis-dabrafenib-trametinib-gliome-pediatrie
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infant
child
malignant glioma
BRAF V600E Mutation Present
Low Grade Glioma
administration, oral
dabrafenib
trametinib
protein kinase inhibitors
antineoplastic agents
guidelines for drug use
Dabrafenib/Trametinib Regimen
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
trametinib
dabrafenib
glioma

---
https://www.has-sante.fr/jcms/p_3146424/fr/tafinlar-mekinist
2020
false
false
false
France
BRAF V600E mutation positive
dabrafenib
dabrafenib
treatment outcome
antineoplastic combined chemotherapy protocols
trametinib
antineoplastic agents
protein kinase inhibitors
trametinib
carcinoma, non-small-cell lung
BRAF protein, human
evaluation of the transparency committee
imidazoles
oximes
pyridones
pyrimidinones
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/portail/jcms/c_2911595/fr/mekinist-tafinlar
2019
false
true
false
false
France
trametinib
dabrafenib
treatment outcome
melanoma
administration, oral
antineoplastic combined chemotherapy protocols
adult
antineoplastic agents
protein kinase inhibitors
melanoma
BRAF V600 Mutation
evaluation of the transparency committee
pyridones
pyrimidinones
imidazoles
oximes

---
https://www.has-sante.fr/portail/jcms/c_2967190/fr/tafinlar
2019
true
France
French
administration, oral
insurance, health, reimbursement
dabrafenib
dabrafenib
dabrafenib
adult
melanoma
antineoplastic agents
antineoplastic agents
BRAF protein, human
evaluation of the transparency committee
neoplasm metastasis
treatment outcome
mutation
survival analysis
Unresectable
BRAF V600E Mutation Present
BRAF V600K Mutation Present
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/portail/jcms/c_2835407/fr/mekinist-tafinlar
https://www.has-sante.fr/portail/jcms/c_2835407/fr/tafinlar-dabrafenib-en-association-a-mekinist-trametinib-inhibiteurs-de-la-proteine-kinase
2018
false
false
false
false
France
French
evaluation of the transparency committee
dabrafenib
dabrafenib
antineoplastic combined chemotherapy protocols
treatment outcome
administration, oral
carcinoma, non-small-cell lung
BRAF V600 Mutation
trametinib
trametinib
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
guidelines for drug use
pyridones
pyrimidinones
pyridones
pyrimidinones
imidazoles
oximes
imidazoles
oximes

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BRAF-en-monotherapie-vemurafenib-dabrafenib-Medicaments-ciblant-BRAF-ou-MEK-en-association-vemurafenib-cobimetinib-dabrafenib-trametinib
2016
false
false
false
France
French
guidelines for drug use
practice guideline
patients guideline
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
administration, oral
drug interactions
vemurafenib
vemurafenib
antineoplastic combined chemotherapy protocols
vemurafenib
dabrafenib
dabrafenib
dabrafenib
BRAF protein, human
Metastatic Melanoma
melanoma
melanoma
neoplasm metastasis
BRAF Gene Mutation
continuity of patient care
drug monitoring
interdisciplinary communication
protein kinase inhibitors
vemurafenib
dabrafenib
pregnancy
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf
imidazoles
oximes
indoles
sulfonamides
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_1742463/fr/tafinlar
2014
false
France
French
administration, oral
insurance, health, reimbursement
dabrafenib
dabrafenib
dabrafenib
adult
melanoma
antineoplastic agents
antineoplastic agents
BRAF protein, human
evaluation of the transparency committee
neoplasm metastasis
treatment outcome
mutation
survival analysis
Unresectable
BRAF V600E Mutation Present
BRAF V600K Mutation Present
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf

---
http://www.meddispar.fr/index.php/Medicaments/TAFINLAR-75-B-120/
2014
false
false
false
France
French
drug information
dabrafenib
dabrafenib
administration, oral
legislation, drug
drug prescriptions
continuity of patient care
capsules
imidazoles
oximes

---
Summary Basis of Decision (SBD) for Tafinlar
Dabrafenib (as dabrafenib mesylate), 50 mg and 75 mg, capsules, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00194
2013
false
Canada
French
English
dabrafenib
melanoma, cutaneous malignant
drug information
Product containing precisely dabrafenib (as dabrafenib mesilate) 50 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely dabrafenib (as dabrafenib mesilate) 75 milligram/1 each conventional release oral capsule (clinical drug)
dabrafenib
dabrafenib
administration, oral
drug approval
canada
proto-oncogene proteins b-raf
protein kinase inhibitors
protein kinase inhibitors
melanoma
melanoma
proto-oncogene proteins b-raf
BRAF protein, human
BRAF protein, human
mutation
adult
treatment outcome
disease-free survival
skin neoplasms
skin neoplasms
imidazoles
imidazoles
oximes
oximes

---
https://www.ema.europa.eu/medicines/human/EPAR/Tafinlar
2013
false
United Kingdom
French
English
dabrafenib
melanoma, cutaneous malignant
drug approval
europe
treatment outcome
dabrafenib
dabrafenib
adult
melanoma
antineoplastic agents
antineoplastic agents
administration, oral
proto-oncogene proteins b-raf
melanoma
mutation
BRAF protein, human
drug interactions
pregnancy
breast feeding
fertility
contraception
protein kinase inhibitors
protein kinase inhibitors
DNA mutational analysis
proto-oncogene proteins b-raf
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
imidazoles
imidazoles
oximes
oximes
skin neoplasms
skin neoplasms
melanoma

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61477322
2013
summary of product characteristics
dabrafenib
dabrafenib
capsules

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60248840
2013
summary of product characteristics
dabrafenib
dabrafenib
capsules

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.